



We Claim:

1. A compound of general formula 1



wherein:



X^- is an anion with a single negative charge;

R is hydrogen, hydroxy, methyl, ethyl, -CF₃, -CHF₂, or fluorine;

R¹ and R², which are identical or different, are each C₁-C₅-alkyl which is optionally substituted by C₃-C₆-cycloalkyl, hydroxy, or halogen, or

R¹ and R² together are a -C₃-C₅-alkylene-bridge; and

R³, R⁴, R^{3'} and R^{4'}, which are identical or different, are each hydrogen, -C₁-C₄-alkyl, -C₁-C₄-alkyloxy, hydroxy, -CF₃, -CHF₂, -CN, -NO₂, or halogen

or a physiologically acceptable salt thereof.

2. The compound of general formula 1 according to claim 1, wherein:

X^- is an anion with a single negative charge selected from chloride, bromide, 4-toluenesulfonate, and methanesulfonate;

R is hydroxy, methyl or fluorine;

R¹ and R², which are identical or different, are each methyl, ethyl, or fluoroethyl; and

R^3 , R^4 , $R^{3'}$ and $R^{4'}$, which are identical or different, are each hydrogen, methyl, methyloxy, hydroxy, $-CF_3$, $-CHF_2$, or fluorine or a physiologically acceptable salt thereof.

3. The compound of general formula 1 according to claim 1, wherein:
 X^- is an anion with a single negative charge selected from chloride, bromide, and methanesulfonate;

R is hydroxy, methyl, or fluorine;

R^1 and R^2 , which are identical or different, are each methyl or ethyl; and
 R^3 , R^4 , $R^{3'}$, and $R^{4'}$, which are identical or different, are each hydrogen, $-CF_3$, $-CHF_2$, or fluorine,

or a physiologically acceptable salt thereof.

4. The compound of general formula 1 according to claim 1, wherein:

X^- is bromide;

R is hydroxy or methyl;

R^1 and R^2 , which are identical or different, are each methyl or ethyl; and

R^3 , R^4 , $R^{3'}$, and $R^{4'}$, which are identical or different, are each hydrogen or fluorine, or a physiologically acceptable salt thereof.

5. A pharmaceutical composition comprising an effective amount of a compound of general formula 1 according to claim 1 or a physiologically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

6. A pharmaceutical composition comprising an effective amount of a compound of general formula 1 according to claim 2 or a physiologically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

7. A pharmaceutical composition comprising an effective amount of a compound of general formula 1 according to claim 3 or a physiologically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

8. A pharmaceutical composition comprising an effective amount of a compound of general formula 1 according to claim 4 or a physiologically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.
9. A pharmaceutical composition according to claim 5, further comprising an additional active substance selected from betamimetics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.
10. A pharmaceutical composition according to claim 6, further comprising an additional active substance selected from betamimetics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.
11. A pharmaceutical composition according to claim 7, further comprising an additional active substance selected from betamimetics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.
12. A pharmaceutical composition according to claim 8, further comprising an additional active substance selected from betamimetics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.
13. A method for treatment of a disease which is responsive to an anticholinergic agent in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 1.

14. A method for treatment of a disease which is responsive to an anticholinergic agent in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 2.
15. A method for treatment of a disease which is responsive to an anticholinergic agent in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 3.
16. A method for treatment of a disease which is responsive to an anticholinergic agent in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 4.
17. A method for treatment of a disease selected from asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, and menstrual pain, in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 1.
18. A method for treatment of a disease selected from asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, and menstrual pain, in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 2.
19. A method for treatment of a disease selected from asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, and menstrual pain, in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 3.

20. A method for treatment of a disease selected from asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, and menstrual pain, in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 4.